Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SubSUF-ER - Sublingual Sufentanil for Emergency Limb Trauma Pain
2024-519217-64-00Phase 4Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sufentanil (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Change in pain intensity from baseline to 60 minutes. Planned start Mar 2025; status: authorised.
02
Drugs
sufentanil
Beyond the preview
Go deeper on 2024-519217-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519217-64-00.